Compare AbbVie Inc (ABBV) vs AMC ENTERTAINMENT HOLDINGS, INC. (AMC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs AMC ENTERTAINMENT HOLDINGS, INC. — how do they compare? AbbVie Inc trades at $252.5 (market cap $449.91B), while AMC ENTERTAINMENT HOLDINGS, INC. trades at $1.85 (market cap $1.54B). The key difference: AbbVie Inc is far larger — about 292.1× AMC ENTERTAINMENT HOLDINGS, INC.'s market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | AMC | |
|---|---|---|
Market Cap | $449.91B | $1.54B |
Sector | Health | Media |
52-Week High | $261.07 | $3.54 |
52-Week Low | $184.85 | $0.95 |
Enterprise Value | $513.38B | $9.13B |
Dividend Yield | 2.72% | 0.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.
The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.
AMC trades at $1.72, down 8.99% in the last session amid dilution concerns from recent equity offerings. The stock shows bearish technical signals with negative cash flows and a net loss of $632.4M in 2025. Recent news highlights summer box office strength but ongoing investor worries about share dilution and profitability. The company's debt remains high at $4.01B, though revenue reached $4.85B in 2025.
Outlook remains challenged by persistent losses and high leverage, though diversification into live events offers growth potential. Key risks include dilution from equity sales and weak cash generation. Analyst consensus is mixed with a $1.85 price target, suggesting limited upside from current levels amid fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About AMC ENTERTAINMENT HOLDINGS, INC.
AMC Entertainment Holdings, Inc. operates as a holding company. The Company, through its subsidiaries, provides theatrical exhibition, movie screening, food distribution, online ticket booking, and other related services. AMC Entertainment offers movie theaters worldwide.
Read more on AMC →
